Author's response to reviews

Title: Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study

Authors:

Teresa Rolle (teresa.rolle@unito.it)

Roberta Spinetta (spinetta.roberta@gmail.com)

Raffaele Nuzzi (prof.nuzzi_raffaele@hotmail.it)

Version: 2 Date: 20 Jul 2017

Author’s response to reviews:

Editor's and Reviewer(s)' Comments to Authors:

Comments to the Author

1) Under your Ethics and consent for participation heading please include the name of the ethics committee that approved the study and the committee’s reference number if appropriate. Please also clarify whether informed consent obtained from participants was written or verbal.

Answer : Dear Editor, thank you for your comments. As suggested, we have included the name of the ethics committee that approved the study and the committee’s reference number under the Ethics and consent for participation heading (DECLARATIONS , Ethics approval and consent to participate, page 13,line 265). We also clarified that informed consent obtained from participants was written (DECLARATIONS , Ethics approval and consent to participate, page 13,line 265).

2) In line with ICMJE guidelines, BioMed Central requires registration of all clinical trials that are reported in manuscripts submitted to its journals. The ICMJE uses the World Health Organization (WHO) definition of a clinical trial, which is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". Suitable publicly available registries are those listed on the ICMJE website as well as any of the primary registries that participate in the WHO International Clinical Trials Registry Platform, including the ISRCTN registry, which is administered and published by BioMed Central.

Answer to 2nd and 3rd points : our study was a cross-sectional observational research so it doesn't match the WHO definition of Clinical Trial.
4) We notice significant text overlap between your manuscript and previously published materials. Please find attached a file containing the iThenticate report for your manuscript. This highlights sections of text which overlap with previous publications. Please reformulate the large sections of highlighted text present in your Methods section. Please understand that we cannot continue with processing your manuscript until this has been completed.

Answer: we reformulated the text present in the Methods section (Methods section from page 4 to page 7).

5) Please note that larger tables should be placed after the references. Therefore, please place table 2 after the references.

Answer: we placed Table 2 after references as suggested.